Title

State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015

UMMS Affiliation

Commonwealth Medicine, Center for Health Policy and Research

Publication Date

2017-11-07

Document Type

Article

Disciplines

Health Economics | Health Law and Policy | Health Policy | Health Services Administration | Health Services Research | Pharmacoeconomics and Pharmaceutical Economics | Virus Diseases

Abstract

New direct-acting antivirals have the ability to cure chronic hepatitis C virus infection, but the costs of these treatments and the number of patients that need them could bring about financial struggles for health systems.

This journal article examines Medicaid reimbursement for HCV medications in the periods before and after the aforementioned direct-acting antivirals were made available. The report also analyzes the the effect of Medicaid expansion on reimbursement for direct-acting antivirals.

Keywords

DAAs, direct-acting antivirals, hepatitis C, Medicaid, sofosbuvir, specialty drugs

DOI of Published Version

10.1016/j.jval.2017.09.011

Source

Christine Y. Lu, Fang Zhang, Nicole Golonski, Caitlin Lupton, Paul Jeffrey, Anita K. Wagner. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value in Health, 2017, https://doi.org/10.1016/j.jval.2017.09.011.

Journal/Book/Conference Title

Value in Health

Share

COinS